29 years of historical data (1996–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
TG Therapeutics, Inc. trades at 200.6x earnings, roughly in line with its 5-year average of 200.5x, sitting at the 100th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a premium of 747%.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4.8B | $4.8B | $2.5B | $1.6B | $2.5B | $6.0B | $981M | $309M | $509M | $228M | $545M |
| Enterprise Value | $4.8B | $4.9B | $2.6B | $1.6B | $2.3B | $5.5B | $909M | $268M | $452M | $203M | $490M |
| P/E Ratio → | 200.60 | 200.67 | 200.23 | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.45 | 14.67 | 10.86 | 575.19 | 375.58 | 39471.44 | 6453.25 | 2035.62 | 3340.12 | 1496.53 | 3573.69 |
| P/B Ratio | 21.70 | 21.70 | 15.80 | 27.34 | 10.59 | 11.55 | 25.40 | 12.87 | 7.60 | 6.36 | 5.36 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
TG Therapeutics, Inc.'s enterprise value stands at 114.4x EBITDA, roughly in line with its 5-year average of 118.7x. The Healthcare sector median is 13.8x, placing the stock at a 726% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.89 | 10.93 | 568.28 | 342.71 | 36106.55 | 5980.67 | 1760.02 | 2968.74 | 1332.71 | 3213.73 |
| EV / EBITDA | 114.40 | 116.09 | 121.31 | — | — | — | — | — | — | — | — |
| EV / EBIT | 115.17 | 98.75 | 99.48 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
TG Therapeutics, Inc. earns an operating margin of 12.7%. Operating margins have expanded from -7839.0% to 12.7% over the past 3 years, signaling improving operational efficiency. ROE of 12.2% is modest. ROIC of 13.3% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.3% | 88.3% | 94.0% | 90.5% | 88.2% | 100.0% | 100.0% | 42.1% | 46.0% | 58.7% | 100.0% |
| Operating Margin | 12.7% | 12.7% | 8.8% | -7839.0% | -5154.3% | -179996.1% | -111220.4% | -114736.8% | -77904.6% | -51823.5% | -41461.9% |
| Net Profit Margin | 7.1% | 7.1% | 5.4% | -8036.3% | -5204.1% | -183803.3% | -113730.9% | -114132.9% | -77749.9% | -51353.4% | -41310.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.2% | 12.2% | 11.6% | -151.4% | -92.0% | -100.1% | -551.9% | -381.2% | -230.4% | -113.9% | -69.3% |
| ROA | 5.2% | 5.2% | 4.8% | -78.1% | -69.3% | -70.8% | -140.2% | -191.7% | -155.7% | -93.0% | -62.9% |
| ROIC | 13.3% | 13.3% | 14.2% | -578.0% | -2052.2% | — | — | — | -835.7% | -205.5% | -132.8% |
| ROCE | 11.0% | 11.0% | 9.9% | -96.0% | -80.9% | -88.7% | -274.2% | -305.5% | -221.2% | -112.1% | -68.5% |
Solvency and debt-coverage ratios — lower is generally safer
TG Therapeutics, Inc. carries a Debt/EBITDA ratio of 6.0x, which is highly leveraged (93% above the sector average of 3.1x). Net debt stands at $74M ($254M total debt minus $180M cash). Interest coverage of just 1.7x is concerning — the company has limited headroom to absorb earnings volatility before struggling with debt service.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.14 | 1.14 | 0.69 | 1.42 | 0.33 | 0.08 | 1.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 6.01 | 6.01 | 5.26 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.33 | 0.11 | -0.33 | -0.93 | -0.98 | -1.86 | -1.74 | -0.84 | -0.70 | -0.54 |
| Net Debt / EBITDA | 1.75 | 1.75 | 0.85 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | 1.75 | 1.75 | 1.64 | -21.42 | -61.15 | -43.23 | -31.98 | -100.58 | -104.18 | — | -64.95 |
Short-term solvency ratios and asset-utilisation metrics
TG Therapeutics, Inc.'s current ratio of 6.25x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 5.03x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 3.16x to 6.25x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.25 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 | 8.25 |
| Quick Ratio | 5.03 | 5.03 | 5.18 | 3.16 | 5.06 | 6.99 | 1.77 | 1.78 | 3.05 | 2.68 | 9.77 |
| Cash Ratio | 3.43 | 3.43 | 4.05 | 3.04 | 4.81 | 6.91 | 1.66 | 1.77 | 3.03 | 2.66 | 7.34 |
| Asset Turnover | — | 0.57 | 0.71 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.35 | 0.35 | 0.35 | — | — | — | — | 0.01 | 0.01 | 0.01 | — |
| Days Sales Outstanding | — | 143.32 | 79.81 | — | 75.79 | — | — | 228.13 | 259.81 | 200.85 | 445.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
TG Therapeutics, Inc. returns 0.2% to shareholders annually primarily through share buybacks. The earnings yield of 0.5% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.5% | 0.5% | 0.5% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $160M | $149M | $135M | $132M | $115M | $88M | $75M | $62M | $49M | $46M |
Compare TGTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| TGTXYou | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| KNSA | $3B | 59.3 | 41.0 | 133.6 | — | 11.4% | 23.6% | 17.1% | 0.1 |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 29 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how TGTX stacks up against sector leader argenx SE.
Start ComparisonTG Therapeutics, Inc.'s current P/E ratio is 200.6x. The historical average is 3.2x. This places it at the 100th percentile of its historical range.
TG Therapeutics, Inc.'s current EV/EBITDA is 114.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
TG Therapeutics, Inc.'s return on equity (ROE) is 12.2%. The historical average is -137.7%.
Based on historical data, TG Therapeutics, Inc. is trading at a P/E of 200.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
TG Therapeutics, Inc. has 88.3% gross margin and 12.7% operating margin. Operating margin between 10-20% is typical for established companies.
TG Therapeutics, Inc.'s Debt/EBITDA ratio is 6.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.